CPT 00148: Anesthesia for Eye Examination Using Endoscope - OpenPayer

Beta

OpenPayer Beta

Summary & Overview

CPT 00148: Anesthesia for Eye Examination Using Endoscope

CPT code 00148 represents anesthesia for eye examinations performed with an endoscope, a specialized procedure that supports accurate diagnosis and management of ocular conditions. This code is significant for both clinical and billing teams, as it defines the scope of anesthesia services required for endoscopic eye exams and is recognized by major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare.

The publication provides a comprehensive overview of CPT 00148, detailing its clinical context, typical sites of service, and its role within the broader anesthesiology service line. Readers will gain insights into payer coverage, relevant policy updates, and benchmarks for anesthesia services in ophthalmology. The article also highlights associated modifiers and taxonomies, as well as related CPT codes and ICD-10 diagnoses commonly linked to this procedure. This information is essential for understanding reimbursement trends, compliance requirements, and the evolving landscape of anesthesia billing for eye examinations using endoscopic techniques.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareCPT 00148anesthesiologyophthalmologyeye examinationendoscopyhospital outpatientsurgery centermedical billingpolicy updateclinical benchmarks

CPT Code Overview

CPT 00148 is used to report anesthesia services provided for eye examinations utilizing an endoscope. This code falls under the anesthesiology service type and is typically performed in a surgery center or hospital outpatient setting. The procedure involves the administration of anesthesia to facilitate a thorough endoscopic examination of the eye, ensuring patient comfort and safety during the diagnostic process.

Clinical & Coding Specifications

Clinical Context

A patient presents to a surgery center or hospital outpatient department for an eye examination requiring the use of an endoscope. The procedure is indicated due to suspected adverse effects from medications acting on muscles or the respiratory system, or from local antifungal, anti-infective, anti-inflammatory drugs, or antipruritics. The patient may have experienced symptoms such as vision changes, pain, or other ocular complications. An anesthesiology physician or certified registered nurse anesthetist (CRNA) provides anesthesia services to ensure patient comfort and safety during the endoscopic eye examination. The clinical workflow involves pre-procedure assessment, administration of anesthesia, monitoring throughout the procedure, and post-procedure recovery.

Coding Specifications

Modifiers:
- QS: Monitored anesthesia care service. Used when anesthesia is provided with continuous monitoring but not general anesthesia.
- QX: CRNA service with medical direction by a physician. Used when a CRNA is medically directed by an anesthesiology physician.
Provider Taxonomies:

Taxonomy Code Specialty

National Reimbursement Benchmarks

National mean rates for CPT code 00148 show that commercial payers, as represented by BUCA, average $114.59, while Medicare rates are not available in the input. Among individual commercial payers, Cigna has the highest mean rate at $249.00, followed by Blue Cross Blue Shield at $220.67, and Aetna at $145.13. UnitedHealth Group is notably lower at $65.62.

Rate dispersion varies significantly across payers. Cigna exhibits the widest spread, with a difference of $258.00 between its 75th and 25th percentiles, indicating substantial variability in reimbursement. In contrast, UnitedHealth Group has the tightest range, with only $25.33 separating its 75th and 25th percentiles, suggesting more consistent rates. The table and chart below present the full breakdown of national benchmarks for each payer.

State Benchmarks

State: AK1 / 50

Alaska Benchmarks

Alaska demonstrates a wide range in reimbursement rates for CPT code 00148 across major commercial payers. The rate spread, calculated as the difference between the 75th and 25th percentiles, is most significant for Blue Cross Blue Shield, with a spread of $74.80 ($300.60 minus $225.80). Aetna and UnitedHealth Group show minimal rate spread, with all percentiles clustered closely around $72.00, indicating limited variability in their payment structures. Cigna's rates are also tightly grouped, with a spread of $8.00.

When compared to national averages, Blue Cross Blue Shield's mean rate in Alaska is substantially higher, while Cigna and UnitedHealth Group are below their respective national means. The table and chart below present the full breakdown of payer-specific reimbursement rates for CPT code 00148 in Alaska.

Key Insights for Alaska

Blue Cross Blue Shield offers the highest mean reimbursement rate for CPT 00148 in Alaska at $268.99, while UnitedHealth Group is the lowest at $75.12.
The rate spread is most pronounced for Blue Cross Blue Shield, with a 75th percentile of $300.60 and a 25th percentile of $225.80, indicating significant variability.
Compared to national averages, Blue Cross Blue Shield's mean rate in Alaska is notably higher, while Cigna and UnitedHealth Group are below their respective national means.

Related Codes

00120

CPT 00120: Anesthesia for Procedures on the Head

00142

CPT 00142: Anesthesia for Eye Lens Surgery

00218

CPT 00218: Anesthesia for Thoracic Spine and Spinal Cord Procedures

00190

CPT 00190: Anesthesia for Facial Bones or Skull Procedures

00124

CPT 00124: Anesthesia for External, Middle & Inner Ear Biopsy with Otoscopy

00170

CPT 00170: Anesthesia for Intraoral Procedures, Including Biopsy

00140

CPT 00140: Anesthesia for Unspecified Eye Procedures

00144

CPT 00144: Anesthesia for Eye Lens Surgery

00147

CPT 00147: Anesthesia for Head Procedures (e.g., Iridectomy)

00126

CPT 00126: Anesthesia for Incision of Eardrum

Showing 1–10 of 36

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Free Report

See how your rates compare to the market.

Get a free custom competitive market analysis.

Free Report

See how your rates compare to the market.

Get a free custom competitive market analysis.

Related Diagnoses

T48.205S: Adverse effect of unspecified drugs acting on muscles, sequela
- Relevant when the eye examination is performed to assess sequelae from drug effects on ocular muscles.
T48.295A: Adverse effect of other drugs acting on muscles, initial encounter
- Used when the procedure is indicated due to an initial adverse drug effect on eye muscles.
T48.295D: Adverse effect of other drugs acting on muscles, subsequent encounter
- Applied for follow-up procedures after an initial adverse drug effect.
T48.295S: Adverse effect of other drugs acting on muscles, sequela
- Used for long-term complications from drug effects on eye muscles.
T48.3X5A: Adverse effect of antitussives, initial encounter
- Relevant if antitussive medications caused ocular symptoms requiring endoscopic examination.
T48.3X5D: Adverse effect of antitussives, subsequent encounter
- Used for follow-up after initial adverse effect from antitussives.
T48.3X5S: Adverse effect of antitussives, sequela
- Applied for sequelae from antitussive drug effects.
T48.4X5A: Adverse effect of expectorants, initial encounter
- Used when expectorants cause adverse ocular effects.
T48.4X5D: Adverse effect of expectorants, subsequent encounter
- For follow-up after initial expectorant-related adverse effect.
T48.4X5S: Adverse effect of expectorants, sequela
- Used for sequelae from expectorant drug effects.
T48.5X5A: Adverse effect of other anti-common-cold drugs, initial encounter
- Relevant for initial adverse effects from anti-common-cold drugs affecting the eye.
T48.5X5D: Adverse effect of other anti-common-cold drugs, subsequent encounter
- Used for follow-up procedures.
T48.5X5S: Adverse effect of other anti-common-cold drugs, sequela
- Applied for sequelae from these drugs.
T48.6X5A: Adverse effect of antiasthmatics, initial encounter
- Used when antiasthmatic drugs cause ocular adverse effects.
T48.6X5D: Adverse effect of antiasthmatics, subsequent encounter
- For follow-up after initial adverse effect.
T48.6X5S: Adverse effect of antiasthmatics, sequela
- Used for sequelae from antiasthmatic drug effects.
T48.905A: Adverse effect of unspecified agents primarily acting on the respiratory system, initial encounter
- Relevant for initial adverse effects from unspecified respiratory agents.
T48.905D: Adverse effect of unspecified agents primarily acting on the respiratory system, subsequent encounter
- Used for follow-up procedures.
T48.905S: Adverse effect of unspecified agents primarily acting on the respiratory system, sequela
- Applied for sequelae from these agents.
T48.995A: Adverse effect of other agents primarily acting on the respiratory system, initial encounter
- Used for initial adverse effects from other respiratory agents.
T48.995D: Adverse effect of other agents primarily acting on the respiratory system, subsequent encounter
- For follow-up after initial adverse effect.
T48.995S: Adverse effect of other agents primarily acting on the respiratory system, sequela
- Used for sequelae from these agents.
T49.0X5A: Adverse effect of local antifungal, anti‑infective and anti‑inflammatory drugs, initial encounter
- Relevant when these drugs cause ocular adverse effects.
T49.0X5D: Adverse effect of local antifungal, anti‑infective and anti‑inflammatory drugs, subsequent encounter
- Used for follow-up procedures.
T49.0X5S: Adverse effect of local antifungal, anti‑infective and anti‑inflammatory drugs, sequela
- Applied for sequelae from these drugs.
T49.1X5A: Adverse effect of antipruritics, initial encounter
- Used when antipruritics cause adverse ocular effects.
T49.1X5D: Adverse effect of antipruritics, subsequent encounter
- For follow-up after initial adverse effect.
T49.1X5S: Adverse effect of antipruritics, sequela
- Used for sequelae from antipruritic drug effects.

Related CPT Codes

CPT Code	Description	Clinical Relationship
`00140`	Anesthesia for procedures on eye; not otherwise specified	Used for general eye procedures requiring anesthesia; alternative to `00148` when endoscope is not used
`00142`	Anesthesia for procedures on eye; lens surgery	Used for lens surgery; may be used instead of `00148` if procedure involves lens rather than endoscopic examination
`00144`	Anesthesia for procedures on eye; corneal transplant	Used for corneal transplant procedures; alternative to `00148` for corneal surgery
`00145`	Anesthesia for procedures on eye; vitreoretinal surgery	Used for vitreoretinal surgery; may be used in place of `00148` if procedure is focused on retina or vitreous
`00147`	Anesthesia for procedures on eye; iridectomy	Used for iridectomy procedures; alternative to `00148` for iris surgery

These codes are related to 00148 and may be used as alternatives depending on the specific eye procedure performed. They are not typically used together but represent anesthesia services for different types of eye surgeries.

National Reimbursement Benchmarks

National Mean Rates by Payer for CPT Code `00148`

State Benchmarks

State: AK1 / 50

Alaska Benchmarks

Mean Reimbursement Rates by Payer in Alaska for CPT 00148

Key Insights for Alaska

Blue Cross Blue Shield offers the highest mean reimbursement rate for CPT 00148 in Alaska at $268.99, while UnitedHealth Group is the lowest at $75.12.
The rate spread is most pronounced for Blue Cross Blue Shield, with a 75th percentile of $300.60 and a 25th percentile of $225.80, indicating significant variability.
Compared to national averages, Blue Cross Blue Shield's mean rate in Alaska is notably higher, while Cigna and UnitedHealth Group are below their respective national means.